Akari Therapeutics (FRA:CLA) Notes Receivable : €0.00 Mil (As of Mar. 2025)

View and export this data going back to 2017. Start your Free Trial

What is Akari Therapeutics Notes Receivable?

Akari Therapeutics's Notes Receivable for the quarter that ended in Mar. 2025 was €0.00 Mil.

Akari Therapeutics Notes Receivable Historical Data

The historical data trend for Akari Therapeutics's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akari Therapeutics Notes Receivable Chart

Akari Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Notes Receivable

Get a 7-Day Free Trial

Akari Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Notes Receivable	Get a 7-Day Free Trial															-	-	-	-	-

Akari Therapeutics Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Akari Therapeutics Notes Receivable Related Terms

Thank you for viewing the detailed overview of Akari Therapeutics's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Akari Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akari Therapeutics PLC (FRA:CLA) » Definitions » Notes Receivable

Comparable Companies

Traded in Other Exchanges

AKTX:USA

Address

22 Boston Wharf Road, 7th Floor, Boston, MA, USA, 02210

Website

https://www.akaritx.com

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.